Protagonist Therapeutics, Inc(PTGX)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Protagonist Therapeutics, Inc (PTGX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PTGX at 59.4/100 on a 32-signal composite quality model, placing it at rank #931 of 2,961 stocks — the top half of the AI-ranked universe. PTGX scores in the top quartile across free cash flow (93.6), profitability (91.8), balance sheet strength (86.0). Areas of concern include revenue scale (28.5) and institutional flow (35.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Protagonist Therapeutics, Inc reports quarterly revenue of $213.5M, net income of $162.8M, free cash flow of $218.9M. Top institutional holders of PTGX by reported 13-F value include BlackRock, FARALLON CAPITAL MANAGEMENT, RTW INVESTMENTS, based on the most recent SEC filings. PTGX trades on the Nasdaq exchange and files with the SEC under CIK 1377121. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PTGX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Protagonist Therapeutics, Inc directly from SEC EDGAR.
AI Quality Score
59.4/100
AI Rank
#931
Revenue
$213.5M
Net Income
$162.8M
Free Cash Flow
$218.9M
PTGX key financials by period
Protagonist Therapeutics, Inc reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$46.0M
$-130.1M
—
FY 2024
10-K
$434.4M
$275.2M
58.2%
FY 2023
10-K
$60.0M
$-79.0M
-156.1%
FY 2022
10-K
$26.6M
$-127.4M
—
FY 2021
10-K
$27.4M
$-125.6M
—
FY 2020
10-K
$28.6M
$-66.2M
—
Institutions holding PTGX
Institutional investors reporting a position in Protagonist Therapeutics, Inc on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
License and collaboration revenue surged to $213.5M in Q2 2026, driven by $200M opt-out payment recognition from Takeda and $50M ICOTYDE FDA approval milestone from JNJ, swinging to $162.8M net income from $34.8M loss year-over-year.
Biggest Revenue Drivers
Takeda Collaboration Agreement opt-out payment recognition$192.4MNew in Q2 2026
Proportional recognition of $200M opt-out payment triggered by exercise of profit-share opt-out right on April 28, 2026
Takeda development services, clinical supplies and other$21.1MNew in Q2 2026
Cost reimbursement for post opt-out wind-down services and rusfertide clinical supplies
Biggest Revenue Drivers
Takeda Collaboration Agreement opt-out payment recognition$192.4MNew in Q2 2026
Proportional recognition of $200M opt-out payment triggered by exercise of profit-share opt-out right on April 28, 2026
Takeda development services, clinical supplies and other$21.1MNew in Q2 2026
Cost reimbursement for post opt-out wind-down services and rusfertide clinical supplies
Largest Expense Items
Research and development$42.1M+14% YoY
Increase driven by PN-881 Phase 1 trial costs ($8.6M), pre-clinical discovery programs ($8.4M), partially offset by rusfertide completion ($12.0M reduction)
General and administrative$12.6M+20% YoY
Increase primarily from personnel-related expenses driven by wage, benefit and stock-based compensation increases
Watch Items from the Filing
Substantial revenue concentration: Q2 revenue of $213.5M is almost entirely from two collaboration partners (Takeda and JNJ); future revenue highly dependent on their regulatory approvals and commercial success.
Company expects R&D expenses to increase significantly in H2 2026 due to PN-881 Phase 2b psoriasis advancement, manufacturing investments, and multiple program initiations (PN-477sc, PN-458, PN-8047).
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
